LymphomaArchives
EBV-miR-BART5-3p promotes the proliferation of Burkitt lymphoma cells via glycolytic pathway
Lymphoma 4 min.
Burkitt lymphoma is a highly aggressive form of B-cell lymphoma that primarily arises within or after the germinal center [1]. Burkitt lymphoma accounts for 30%−50% of childhood tumors in Africa reported by the World Health Organization (WHO) [2, 3]. Unfortunately, the incidence of this condition...
Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000–2025)
Lymphoma 12 min.
The earliest attempt to mobilize human immune system against cancer dated back to the late nineteenth century with William Coley’s use of bacterial mixtures, later called Coley’s toxins [1]. Cancer immunotherapy stalled for decades until the discovery and characterization of negative regulators...
Brentuximab vedotin combined with cisplatin, cytarabine, and dexamethasone treatment in transplant-eligible Korean patients with relapsed or refractory Hodgkin’s lymphoma
Lymphoma 3 min.
Patients with classical Hodgkin’s lymphoma (HL) are usually treated with front-line combination chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). However, approximately 10–30% of patients suffer from relapsed or refractory disease [1], and the current standard...
Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphoma
Lymphoma 5 min.
Central nervous system lymphoma (CNSL) is a highly aggressive subset of non-Hodgkin lymphoma with a dismal prognosis, including primary CNSL (PCNSL) and secondary CNSL (SCNSL) [1]. PCNSL is a distinct form of lymphoma confined to the brain, spinal cord, leptomeninges, or eyes, with no evidence of systemic...
Development and internal validation of a lymphoma-specific nomogram for predicting venous thromboembolism: a retrospective cohort of 790 patients
Lymphoma 4 min.
Thromboembolism is a serious complication in patients with cancer, occurring 4 to 7 times more frequently than in the general population, with a mortality risk that is 6 to 8 times higher [1, 2–3]. Lymphoma patients are especially susceptible, with recent studies indicating that the incidence of...
